









市場行情
/
股票
/
nasdaq-crbp
/

Corbus Pharmaceuticals Holdings Inc

CRBP

8.120USD

+0.020+0.25%

收盤 12/19, 16:00（美東）報價延遲15分鐘

101.78M總市值

虧損本益比TTM



Corbus Pharmaceuticals Holdings Inc

8.120

+0.020+0.25%

概覽公司財務分析

概覽

公司

財務

分析

關於 Corbus Pharmaceuticals Holdings Inc 公司

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Corbus Pharmaceuticals Holdings Inc簡介



公司代碼CRBP

公司名稱Corbus Pharmaceuticals Holdings Inc

上市日期Oct 24, 2014

CEOCohen (Yuval)

員工數量28

證券類型Ordinary Share

年結日Oct 24

公司地址500 River Ridge Drive

城市NORWOOD

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02062

電話16179630103

網址https://www.corbuspharma.com/

公司代碼CRBP

上市日期Oct 24, 2014

CEOCohen (Yuval)

Corbus Pharmaceuticals Holdings Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Sean F. Moran, CPA

Chief Financial Officer

15.68K

Dr. Yuval Cohen, Ph.D.

Chief Executive Officer, Director

14.63K

Mr. Alan F. Holmer, J.D.

Independent Director

7.85K

+157.58%

Dr. Dominic Smethurst

Chief Medical Officer

6.11K

-92.09%

Dr. Yong Ben, M.D., Ph.D.

Independent Director

4.80K

Ms. Rachelle Suzanne Jacques

Independent Chairman of the Board

4.80K

Dr. Anne Altmeyer, Ph.D.

Independent Director

3.41K

Dr. Ian Hodgson

Chief Operating Officer

1.23K

Dr. John Kenneth Jenkins, M.D.

Independent Director

Mr. Winston W. Kung

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Sean F. Moran, CPA

Chief Financial Officer

15.68K

Dr. Yuval Cohen, Ph.D.

Chief Executive Officer, Director

14.63K

Mr. Alan F. Holmer, J.D.

Independent Director

7.85K

+157.58%

Dr. Dominic Smethurst

Chief Medical Officer

6.11K

-92.09%

Dr. Yong Ben, M.D., Ph.D.

Independent Director

4.80K

Ms. Rachelle Suzanne Jacques

Independent Chairman of the Board

4.80K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月2日週二

持股股東

股東類型

持股股東

佔比

Cormorant Asset Management, LP

13.36%

OrbiMed Advisors, LLC

6.68%

Octagon Capital Advisors LP

6.35%

Citadel Advisors LLC

5.59%

The Vanguard Group, Inc.

3.49%

其他

64.54%

持股股東

佔比

Cormorant Asset Management, LP

13.36%

OrbiMed Advisors, LLC

6.68%

Octagon Capital Advisors LP

6.35%

Citadel Advisors LLC

5.59%

The Vanguard Group, Inc.

3.49%

其他

64.54%

股東類型

持股股東

佔比

Hedge Fund

32.79%

Investment Advisor

7.70%

Private Equity

6.68%

Investment Advisor/Hedge Fund

6.14%

Venture Capital

2.45%

Research Firm

1.93%

Bank and Trust

1.16%

Individual Investor

0.43%

其他

40.72%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

244

9.91M

80.52%

+983.33K

2025Q3

247

9.76M

113.59%

-275.42K

2025Q2

241

10.04M

128.17%

-1.37M

2025Q1

238

11.57M

122.09%

-3.37M

2024Q4

247

12.14M

125.11%

-689.52K

2024Q3

235

12.83M

99.91%

+494.88K

2024Q2

203

12.32M

76.88%

+2.31M

2024Q1

161

10.21M

42.49%

+5.75M

2023Q4

129

1.15M

32.26%

+195.69K

2023Q3

138

958.46K

32.32%

+8.70K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Cormorant Asset Management, LP

2.38M

19.38%

Jun 30, 2025

OrbiMed Advisors, LLC

1.17M

9.57%

Jun 30, 2025

Octagon Capital Advisors LP

1.11M

9.1%

Jun 30, 2025

The Vanguard Group, Inc.

599.50K

4.89%

-72.56K

-10.80%

Jun 30, 2025

Prosight Capital

579.89K

4.73%

+4.76K

+0.83%

Jun 30, 2025

Exome Asset Management LLC

277.32K

2.26%

-12.37K

-4.27%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

336.42K

2.75%

-454.48K

-57.46%

Jun 30, 2025

Comerica, Inc.

200.00K

1.63%

Jun 30, 2025

Armistice Capital LLC

192.00K

1.57%

-58.00K

-23.20%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.01%

Pacer WealthShield ETF

Harbor Health Care ETF

ProShares Hedge Replication ETF

Tema Oncology ETF

Schwab U.S. Broad Market ETF

iShares Core S&P Total U.S. Stock Market ETF

Vanguard US Momentum Factor ETF

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

佔比0.03%

Avantis US Small Cap Equity ETF

佔比0.01%

Pacer WealthShield ETF

佔比0%

Harbor Health Care ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

Tema Oncology ETF

佔比0%

Schwab U.S. Broad Market ETF

佔比0%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

Vanguard US Momentum Factor ETF

佔比0%

Fidelity Enhanced Small Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

公告日期

類型

比率

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

常見問題

Corbus Pharmaceuticals Holdings Inc的前五大股東是誰？



Corbus Pharmaceuticals Holdings Inc的前五大股東如下：
Cormorant Asset Management, LP
持有股份：2.38M
佔總股份比例：19.38%。
OrbiMed Advisors, LLC
持有股份：1.17M
佔總股份比例：9.57%。
Octagon Capital Advisors LP
持有股份：1.11M
佔總股份比例：9.10%。
The Vanguard Group, Inc.
持有股份：599.50K
佔總股份比例：4.89%。
Prosight Capital
持有股份：579.89K
佔總股份比例：4.73%。